MCL1 and lung carcinoma: In this study, we further confirmed that RT also had anti-cancer activities as well as Mcl-1-targeted activity in patient-derived primary lung cancer cells, with a lower IC50 compared to other first-line chemotherapeutic drugs (Figure 1b–g, Figure 3a,b).